MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
48.27
-1.76
-3.52%
Opening 13:17 09/29 EDT
OPEN
49.93
PREV CLOSE
50.03
HIGH
50.00
LOW
47.64
VOLUME
373.81K
TURNOVER
13.10M
52 WEEK HIGH
55.80
52 WEEK LOW
29.26
MARKET CAP
4.54B
P/E (TTM)
-18.6090
1D
5D
1M
3M
1Y
5Y
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOB...
GlobeNewswire · 1d ago
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLESOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentat...
GlobeNewswire · 3d ago
Insider Sell: Cytokinetics
Insider Sell: Cytokinetics
MT Newswires · 09/21 16:06
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Benzinga · 09/07 09:16
BRIEF-Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BRIEF-Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 09/01 20:03
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $69 From $56, Reiterates Overweight Rating
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $69 From $56, Reiterates Overweight Rating
MT Newswires · 08/15 07:45
--Oppenheimer Adjusts Cytokinetics Price Target to $60 From $57, Maintains Outperform Rating
--Oppenheimer Adjusts Cytokinetics Price Target to $60 From $57, Maintains Outperform Rating
MT Newswires · 08/10 10:41
Hot Stocks: IRBT jumps on AMZN merger deal; CYTK rallies; WBD, HYZN drop
The release of stronger-than-expected jobs data led to a lackluster session on Wall Street, as investors worried that the Federal Reserve would have additional runway to enact an aggressive plan to raise interest rates. The major averages finished Frida...
Seekingalpha · 08/05 21:52
More
About CYTK
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. It is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv (CK-2127107), a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten (CK-274), a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-3772271 (CK-271), a second novel cardiac myosin inhibitor.

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.